Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 239 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 More Immunotherapy Options Approved for Treating Endometrial Cancer August 6, 2024 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 Load more HOT NEWS Rate of Suicides Related to Cancer Is Declining Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show
